Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera, Inc. (NASDAQ: NTRA) announced the publication of its DEDUCE study in the Journal of Heart and Lung Transplantation, demonstrating the effectiveness of its Prospera™ Heart test in assessing acute rejection in heart transplant patients. The study analyzed 703 prospective samples, achieving an impressive AUC of 0.86. The test shows potential to replace invasive biopsies and is backed by further trials, including NIH-supported studies anticipated to involve over 775 patients. This advancement highlights Natera's commitment to precision in heart transplant care.
Natera, Inc. (NASDAQ: NTRA) announced new findings regarding its Signatera personalized molecular residual disease test at the American Association for Cancer Research annual meeting held from April 8-13, 2022. The data focuses on triple negative breast cancer (TNBC) and high-risk hormone receptor-positive/HER2-negative patients. Key results include a significant correlation between detectable circulating tumor DNA (ctDNA) post-surgery and poor outcomes, with a lead time of up to 30 months before recurrence. This reinforces Signatera's role in enhancing patient management for breast cancer.
Natera, Inc. (NASDAQ: NTRA) announced the publication of the VALID study, validating its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test for assessing lung transplant rejection. The study analyzed 195 biopsy-matched samples, demonstrating the test's robust performance, with a 0.91 AUC for acute rejection against stable cases. Already in use at 25% of U.S. lung transplant centers, the Prospera test promises improved patient outcomes in lung transplantation. The study was published in Transplant Direct.
Natera, Inc. (NASDAQ: NTRA) announced the appointment of Sangeeta Bhorade, M.D., as the new vice president of organ health medical affairs.
Dr. Bhorade brings over 27 years of experience, including her role at the University of Chicago and Northwestern University. This addition follows other key hires, enhancing Natera's leadership in organ health. Her expertise is expected to drive innovation and improve patient care. With this new leadership, Natera aims to strengthen its position in the organ health sector.
Natera, Inc. (NASDAQ: NTRA) announced a study published in Transplantation Proceedings that highlights the significance of total cell-free DNA (cfDNA) testing in kidney transplant recipients hospitalized with COVID-19. Using its Prospera™ test, the study reveals that elevated total cfDNA can obscure donor-derived cfDNA (dd-cfDNA) levels, potentially masking transplant rejection cases. The Prospera test identified two patients whose biopsy-proven rejections were undetected by dd-cfDNA alone. This research underscores the necessity of total cfDNA in understanding graft health amidst COVID-19 challenges.
Natera, a leader in cell-free DNA testing, has been recognized by Fast Company in its annual list of the World's Most Innovative Companies for 2022. The company ranked sixth in the Health category, acknowledged for its Signatera™ MRD test, which effectively monitors therapy response and predicts patient benefit from immunotherapy across various cancer types. This recognition highlights the test's significant impact, particularly after Medicare's approval for its serial use in pan-cancer immunotherapy monitoring.
Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.
Natera, a global leader in cell-free DNA testing, has published a study in Transplantation showing that its Prospera™ technology effectively assesses pancreas graft rejection in simultaneous pancreas-kidney transplants. Conducted at the Hospital Clinic of Barcelona, the study involved 36 transplant recipients and highlighted that the combination of donor-derived cell-free DNA (dd-cfDNA) quantity and fraction significantly outperformed existing biochemical markers, achieving a sensitivity of 85.7% and specificity of 93.7%. This advancement positions Natera for improved clinical outcomes in transplant care.
Natera announced new data from the CIRCULATE-Japan trial, revealing a 75% detection rate of colorectal cancer recurrence from a single blood draw four weeks post-surgery. This update, presented at the SSO 2022 conference, indicates improved outcomes for patients identified through Natera's Signatera test. The CIRCULATE-Japan study is the largest clinical trial focusing on molecular residual disease in colorectal cancer, enrolling over 3,300 patients to date. Additionally, Natera activated the CIRCULATE-US trial to further explore MRD-guided treatment strategies.
Natera, Inc. (NASDAQ: NTRA) announced a $5 million investment in its stock by Roelof Botha, lead independent director and partner at Sequoia Capital, reflecting his confidence in the company’s future. Botha has worked closely with Natera for 15 years, emphasizing his commitment to its strategic and commercial execution. Additionally, Natera's executives and non-employee directors will convert their cash compensation to equity for the remainder of 2022. This move indicates a strong internal belief in the company's potential, focusing on genetic testing's role in healthcare.